Tesamorelin: Keep the Indication Attached
AXON Research Institute • AXON Peptide affiliation
Educational draft • Scientific + legal review pending
Silent film with full on-screen captions. Conceptual illustrations, not molecular structures.

Tesamorelin is a growth hormone-releasing factor analog. Its US prescribing information addresses a specific clinical problem: excess abdominal fat in adults with HIV-associated lipodystrophy. The clinical studies evaluated visceral fat in that population. This evidence should not be converted into a general promise of weight loss or rejuvenation. The label explicitly says tesamorelin is not indicated for weight-loss management. It also states that long-term cardiovascular safety has not been established. Important risks include glucose intolerance, elevated IGF-1 and fluid retention. Product identity, patient population and outcome must stay attached when summarizing the research.

END CARD
Educational draft. Not medical advice. Sources and limitations accompany this film.

SOURCES
[1] FDA (March 2025): EGRIFTA WR (tesamorelin) prescribing information
https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/022505s020lbl.pdf
Official US prescribing information and clinical-study summary

EVIDENCE LIMITATIONS
The authorized indication is specific to adults with HIV-associated lipodystrophy.
Do not infer a general obesity, bodybuilding or anti-aging indication.
The label distinguishes EGRIFTA WR and EGRIFTA SV and states they are not substitutable.

TOPIC INVENTORY PROVENANCE (not reused audiovisual media)
Tesamorelin: Begin With the Specific Studied and Approved Indication